Armin Schulz
Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.
After graduating, he worked as an IT consultant for a listed company before becoming self-employed, during which time he worked for various DAX-listed companies and a large Swiss insurance company, among others.
Since 2009, he has been exclusively involved in the capital markets, where he was able to gain experience as a day and swing trader, in investor relations and at board level. He was able to live out his passion for numbers in the controlling department of a securities trading house.
For him, fundamental analysis paired with the correct reading of the price action of a market provides the basis for successful trading.
Commented by Armin Schulz
Commented by Armin Schulz on July 10th, 2025 | 07:15 CEST
How BioNTech, PanGenomic Health, and Pfizer are using artificial intelligence to cut costs and boost returns
Digitalization is revolutionizing the biotechnology and pharmaceutical industries. Artificial intelligence sifts through billions of pieces of medical data in real time, accelerating drug development by years. This is also demonstrated by the new alliance between Moderna and Google Cloud, which are jointly developing an AI platform for customized mRNA cancer therapies. These technologies reduce production costs by up to 40% and generate disruptive return opportunities. At the same time, personalized medicine is opening up billion-dollar markets. Three companies are turning to artificial intelligence to boost their returns: BioNTech, PanGenomic Health, and Pfizer.
Read
Commented by Armin Schulz on July 10th, 2025 | 07:05 CEST
Deutsche Telekom, MiMedia, Xiaomi: Three stocks benefiting from the cloud and AI revolution
By 2025, cloud services and artificial intelligence (AI) will become increasingly important. AI infrastructures have become a critical competitive nerve center. Hyperscaling and agentic systems are revolutionizing value chains; those who hesitate will lose out. The drivers are platforms such as Microsoft's new AI cloud generation, which enables the real-time integration of generative AI into core processes. This hyperscaling reduces costs, enhances data protection, and accelerates AI adoption in data-intensive sectors. A billion-dollar market is emerging for pioneers. Three players have strategically positioned themselves: Deutsche Telekom, MiMedia, and Xiaomi.
Read
Commented by Armin Schulz on July 9th, 2025 | 07:05 CEST
Liver cancer breakthrough fuels billion-dollar market: How Bayer, Vidac Pharma, and Novo Nordisk can now power your portfolio
The pharmaceutical industry is undergoing its biggest upheaval in decades. Megatrends such as cancer treatment, fueled by recent breakthroughs like the EMA approval of the liver cancer therapy Lenvima®/Keytruda®, and revolutionary therapies for diabetes and obesity are generating billion-dollar markets. Those who understand these growth drivers will identify lucrative opportunities. Innovative active ingredients are not only changing medicine but also unlocking exceptional return potential for forward-thinking investors. This dynamic draws attention directly to the strategies of Bayer, Vidac Pharma, and Novo Nordisk.
Read
Commented by Armin Schulz on July 8th, 2025 | 07:00 CEST
Tungsten and molybdenum for the US military and Elon Musk: Why Almonty's NASDAQ listing could provide the next boost
Tungsten is harder than steel and only melts at 3,422 degrees - no wonder it is used in rockets, industrial robots, semiconductors, and many other high-tech applications. However, 84% of the world's critical metal comes from China, which poses a strategic risk to the West. Since the Chinese government imposed export restrictions, there has been significant upheaval. This is where Almonty Industries comes in. With mines in South Korea, Portugal, and Spain, the Company is building the largest independent tungsten pipeline outside China. For investors, Almonty is thus becoming a lever for raw material independence.
Read
Commented by Armin Schulz on July 7th, 2025 | 07:10 CEST
RENK, Globex Mining, BYD: The raw materials gap – A threat to defense and e-mobility, An opportunity for miners
Global industry is facing a turning point. While defense giants like RENK are experiencing record demand yet continue to face investor skepticism, and electric vehicle leader BYD grapples with market saturation, raw materials are redefining the competitive landscape. Raw materials such as tungsten, antimony, and rare earths are essential for high-tech industries. Globex Mining is directly benefiting from this shortage of strategic metals – an effect that is permeating supply chains, from tank manufacturing to electric vehicle production. The diverging paths of these three players underscore the importance of supply security in determining success. An analysis of the current status of RENK, Globex Mining, and BYD reveals the strategic levers for future value creation.
Read
Commented by Armin Schulz on July 3rd, 2025 | 07:20 CEST
Desert Gold's ingenious move: How the untapped gold anomaly and upcoming PEA could significantly enhance your portfolio
What if there were a vast, largely unexplored area right next to some of West Africa's most productive gold mines? And what if strong gold traces had already been found on surface, but no drill had ever been set up there? Desert Gold Ventures is now seizing this opportunity with the Tiegba Project in Ivory Coast. The deal is more than just a new exploration field. It is a strategically astute move with the potential to fundamentally transform the Company. Investors looking for exceptional opportunities in the commodities sector would be well advised to take a closer look.
Read
Commented by Armin Schulz on July 2nd, 2025 | 07:10 CEST
AI, personalized therapies, blockbusters: Evotec, NetraMark Holdings, Novo Nordisk – Your ticket to the pharmaceutical boom
As billion-dollar profits beckon and technological quantum leaps revolutionize the healthcare industry, investor excitement is surging in 2025. Investors are flocking back, attracted by unprecedented momentum. Artificial intelligence is discovering new drug candidates in record time, personalized medicine is unlocking entirely new markets, and solutions for widespread chronic diseases are driving valuations to dizzying heights. Those who understand the rules of this rapid change and identify the right partners are positioning themselves for exceptional returns. We therefore take a closer look at three compelling companies in this space: Evotec, NetraMark Holdings, and Novo Nordisk.
Read
Commented by Armin Schulz on July 2nd, 2025 | 07:00 CEST
From microcap to market leader: How to get in on the booming billion-dollar graphene market with Argo Living Soils
Graphene sounds like something out of a science fiction novel, but it is already being used today where it matters most: in our roads and buildings. This miracle material, which is 200 times stronger than steel and as conductive as copper, is revolutionizing concrete and asphalt. It makes infrastructure more durable, drastically reduces CO₂ emissions, and lowers construction costs. For investors, this creates a perfect storm of technological advancement and sustainability pressure. Those who get in early with the companies driving this change will position themselves at the forefront of a billion-dollar market.
Read
Commented by Armin Schulz on June 30th, 2025 | 07:05 CEST
Gold on track for a new all-time high: How to profit with Barrick Mining, AJN Resources, and Newmont
Gold is heading inexorably toward new records in 2025, driven by geopolitical crises, fluctuating currencies, and nervous markets. Following a rapid start to the year, the price surged to historic highs, driven by substantial demand from investors and central banks. Interestingly, Asian private investors, in particular, have jumped on the gold bandwagon. If Asian "gold bugs" are now also on board, their purchasing power could support the market. Experts predict further increases, potentially reaching USD 3,956, especially with the strong season just beginning. Anyone looking to profit from this dynamic rally should keep an eye on these three companies: Barrick Mining, AJN Resources, and Newmont.
Read
Commented by Armin Schulz on June 26th, 2025 | 07:15 CEST
NATO's 5% target: Why Almonty Industries' mega mine and NASDAQ listing are a perfect fit for investors
Geopolitical conflicts and trade restrictions are making it increasingly difficult to source critical raw materials. Western companies in the high-tech and defense sectors are particularly struggling with scarce supplies and increasingly stringent export controls. With NATO's new 5% defense spending target, the battle for raw materials such as tungsten, which are essential for defense equipment, is set to gain further momentum. As a result, the demand for independent suppliers and the need for reliable partners with sufficient capacity is growing. Almonty Industries has already established a unique profile as a tungsten producer, with assets ranging from mines in Europe to the upcoming commissioning of a mega deposit in South Korea.
Read